Does IDARUCIZUMAB Cause Malignant neoplasm progression? 5 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 5 reports of Malignant neoplasm progression have been filed in association with IDARUCIZUMAB (Praxbind). This represents 0.3% of all adverse event reports for IDARUCIZUMAB.
5
Reports of Malignant neoplasm progression with IDARUCIZUMAB
0.3%
of all IDARUCIZUMAB reports
4
Deaths
0
Hospitalizations
How Dangerous Is Malignant neoplasm progression From IDARUCIZUMAB?
Of the 5 reports, 4 (80.0%) resulted in death.
Is Malignant neoplasm progression Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for IDARUCIZUMAB. However, 5 reports have been filed with the FAERS database.
What Other Side Effects Does IDARUCIZUMAB Cause?
Death (170)
Haemorrhage (110)
Cerebral haemorrhage (92)
Gastrointestinal haemorrhage (83)
Haemorrhage intracranial (68)
Multiple organ dysfunction syndrome (68)
Drug ineffective (58)
Pneumonia (51)
Acute kidney injury (49)
Cerebral infarction (46)
What Other Drugs Cause Malignant neoplasm progression?
PEMBROLIZUMAB (10,111)
NIVOLUMAB (9,363)
ENZALUTAMIDE (4,696)
CARBOPLATIN (4,177)
EVEROLIMUS (3,789)
PACLITAXEL (3,484)
LETROZOLE (3,445)
IPILIMUMAB (3,296)
FULVESTRANT (3,221)
LENVATINIB (2,929)
Which IDARUCIZUMAB Alternatives Have Lower Malignant neoplasm progression Risk?
IDARUCIZUMAB vs IDECABTAGENE VICLEUCEL
IDARUCIZUMAB vs IDELALISIB
IDARUCIZUMAB vs IDURSULFASE
IDARUCIZUMAB vs IFOSFAMIDE
IDARUCIZUMAB vs IGURATIMOD